Physician profile
Marla Smith
NPI 1548444011
$2,203.19
in general payments reported to CMS, 2019-2025
22 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $642 · 2023: $669 · 2024: $344 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.61 | 2021-2025 | |
| Evofem Biosciences, INC. | $305.99 | 2022-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $289.84 | 2021-2025 | |
| Organon LLC | $244.07 | 2021-2024 | Nexplanon |
| Agile Therapeutics, INC. | $157.70 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $128.50 | 2022-2025 | Slynd |
| Mylan Pharmaceuticals INC. | $97.91 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $96.50 | 2024 | |
| Hologic Sales and Service, LLC | $95.46 | 2022-2024 | Thinprep 2000 Processor, Third Wave, Aptima |
| Sumitomo Pharma America, INC. | $60.57 | 2023 | Myfembree |
| Exact Sciences Corporation | $44.61 | 2023 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $38.55 | 2021-2022 | |
| Avion Pharmaceuticals | $31.30 | 2021-2022 | |
| Lupin INC. | $20.69 | 2021 | |
| Dexcom, INC. | $20.05 | 2023 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optumhealth Care Solutions, LLC | $18.86 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Lilly USA, LLC | $16.21 | 2024 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $15.43 | 2022 | |
| Millicent US INC | $15.06 | 2025 | Femlyv |
| Smith+Nephew, INC. | $13.81 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.